Histone deacetylase-mediated transcriptional activation reduces proviral loads in HTLV-1-associated myelopathy/tropical spastic paraparesis patients

Blood

Volumn 110, Issue 10, 2007, Pages 3722-3728

  Lezin, Agnès ^a   Gillet, Nicolas ^b   Olindo, Stéphane ^a   Signaté, Aïssatou ^a   Grandvaux, Nathalie ^c   Verlaeten, Olivier ^b   Belrose, Gildas ^a   Bittencourt, Marcelo De Carvalho ^a   Hiscott, John ^d   Asquith, Becca ^e   Burny, Arsène ^b   Smadja, Didier ^a   Césaire, Raymond ^a   Willems, Luc ^b,f  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE FORT DE FRANCE   (France)

^b Academie universitaire Wallonie Bruxelles   (Belgium)

^c UNIVERSITY OF MONTREAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f FUND FOR SCIENTIFIC RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CORE PROTEIN; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; PROTEIN P19; VALPROIC ACID;

ACETYLATION; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EPILEPSY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNE RESPONSE; PRIORITY JOURNAL; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE; TRANSCRIPTION INITIATION; VIRUS GENE; VIRUS LOAD; VIRUS REPLICATION; WESTERN BLOTTING;

EID: 36348934612     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-04-085076     Document Type: Article

References (35)

1. Gallo RC. History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2. Oncogene. 2005;24:5926-5930.
2. Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet. 1985;2:407-410.
3. Yoshida M. Discovery of HTLV-1, the first human retrovirus, its unique regulatory mechanisms, and insights into pathogenesis. Oncogene. 2005;24:5931-5937.
4. Nakagawa M, Nakahara K, Maruyama Y, et al. Therapeutic trials in 200 patients with HTLV-Iassociated myelopathy/tropical spastic paraparesis. J Neurovirol. 1996;2:345-355.
5. Oh U, Yamano Y, Mora CA, et al. Interferon-beta 1a therapy in human T-lymphotropic virus type I-associated neurologic disease. Ann Neurol. 2005;57:526-534.
6. Saito M, Nakagawa M, Kaseda S, et al. Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-Iassociated myelopathy/tropical spastic paraparesis. J Infect Dis. 2004;189:29-40.
7. Ikegami M, Umehara F, Ikegami N, Maekawa R, Osame M. Selective matrix metalloproteinase inhibitor, N-biphenyl sulfonyl phenylalanine hydroxamic acid, inhibits the migration of CD4(+) T lymphocytes in patients with HTLV-I-associated myelopathy. J Neuroimmunol. 2002;127:134-138.
8. Machuca A, Soriano V. In vivo fluctuation of HTLV-I and HTLV-II proviral load in patients receiving antiretroviral drugs. J AIDS. 2000;24:189-193.
9. Sheremata WA, Benedict D, Squilacote DC, Sazant A, Defreitas E. High-dose zidovudine induction in HTLV-I-associated myelopathy: safety and possible efficacy. Neurology. 1993;43:2125-2129.
10. Taylor GP, Hall SE, Navarrete S, et al. Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy. J Virol. 1999;73:10289-10295.
11. Achachi A, Florins A, Gillet N, et al. Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo. Proc Natl Acad Sci U S A. 2005;102:10309-10314.
12. Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005;366:549-555.
13. Bangham CRM, Osame M. Cellular immune response to HTLV-1. Oncogene. 2005;24:6035-6046.
14. Saito M, Higuchi I, Saito A, et al. Molecular analysis of T cell clonotypes in muscle-infiltrating lymphocytes from patients with human T lymphotropic virus type 1 polymyositis. J Infect Dis. 2002;186:1231-1241.
15. Jacobson S. Immunopathogenesis of human T cell lymphotropic virus type I-associated neurologic disease. J Infect Dis. 2002;186:S187-S192.
16. Levin MC, Lee SM, Kalume F, et al. Autoimmunity due to molecular mimicry as a cause of neurological disease. Nat Med. 2002;8:509-513.
17. Nagai M, Usuku K, Matsumoto W, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol. 1998;4:586-593.
18. Olindo S, Lezin A, Cabre P, et al. HTLV-1 proviral load in peripheral blood mononuclear cells quantified in 100 HAM/TSP patients: a marker of disease progression. J Neurol Sci, 2005;237:53-59.
19. Taylor GP, Tosswill JHC, Matutes E, et al. Prospective study of HTLV-I infection in an initially asymptomatic cohort. J AIDS. 1999;22:92-100.
20. Matsuzaki T, Nakagawa M, Nagai M, et al. HTLV-I proviral load correlates with progression of motor disability in HAM/TSP: analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years. J Neurovirol. 2001;7:228-234.
21. Takenouchi N, Yamano Y, Usuku K, Osame M, Izumo S. Usefulness of proviral load measurement for monitoring of disease activity in individual patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Neurovirol. 2003;9:29-35.
22. Mortreux F, Leclercq I, Gabet AS, et al. Somatic mutation in human T-cell leukemia virus type 1 provirus and flanking cellular sequences during clonal expansion in vivo. J Natl Cancer Inst. 2001;93:367-377.
23. Moritoyo T, Izumo S, Moritoyo H, et al. Detection of human T-lymphotropic virus type I p40tax protein in cerebrospinal fluid cells from patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Neurovirol. 1999;5:241-248.
24. Yamano Y, Nagai M, Brennan M, et al. Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8(+) T cells, and disease severity in HTLV-1-associated myelopathy (HAM/TSP). Blood. 2002;99:88-94.
25. Osame M, Janssen R, Kubota H, et al. Nationwide Survey of Htlv-I Associated Myelopathy in Japan: association with blood-transfusion. Ann Neurol. 1990;28:50-56.
26. Lezin A, Olindo S, Oliere S, et al. Human T lymphotropic virus type I (HTLV-I) proviral load in cerebrospinal fluid: a new criterion for the diagnosis of HTLV-I-associated myelopathy/tropical spastic paraparesis? J Infect Dis. 2005;191:1830-1834.
27. Drummond DC, Noble CO, Kirpotin DB, et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Ann Rev Pharmacol Toxicol. 2005;45:495-528.
28. Blaheta RA, Nau H, Michaelis M, Cinatl J. Valproate and valproate-analogues: Potent tools to fight against cancer. Curr Med Chem. 2002;9:1417-1433.
29. Kwaan N, Lee TH, Chafets DM, et al. Long-term variations in human T lymphotropic virus (HTLV)-I and HTLV-II proviral loads and association with clinical data. J Infect Dis. 2006;194:1557-1564.
30. Mosley AJ, Meekings KN, McCarthy C, et al. Histone deacetylase inhibitors increase virus gene expression but decrease CD8+ cell antiviral function in HTLV-1 infection. Blood. 2006;108:3801-3807.
31. Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai LH. Recovery of learning and memory is associated with chromatin remodelling. Nature. 2007;447:178-182.
32. Insinga A, Monestiroli S, Ronzoni S, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med. 2005;11:71-76.
33. Nebbioso A, Clarke N, Voltz E, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med. 2005;11:77-84.
34. Camelo S, Iglesias AH, Hwang D, et al. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol. 2005;164:10-21.
35. Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, et al. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer: a phase I study. Mol Cancer (http://www.molecular-cancer.com). 2005;4:22. Accessed July 7, 2005.